Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer

Jeff A Sloan, Richard M. Goldberg, Daniel J. Sargent, Delfino Vargas-Chanes, Suresh Nair, Steven S. Cha, Paul J. Novotny, Michael A. Poon, Michael J. O'Connell, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Purpose: The toxicity profile of fluorouracil (5-FU)-based chemotherapy given on 5 consecutive days at doses of 370 to 450 mg/m2 has been well documented. A meta-analysis of six North Central Cancer Treatment Group (NCCTG) cancer control trials involving 786 patients indicated that women treated with this type of regimen experienced more severe stomatitis and leukopenia than men. After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken. Methods: Data for 1,093 women and 1,355 men from 12 different treatment arms were included. The primary end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, recorded with standard National Cancer Institute common toxicity criteria. Fisher's exact test was used to compare incidence and severity across sexes, supplemented by Forrest meta-analysis plots and logistic regression. Results: The incidence of four out of six toxicities studied was significantly greater for women than men; the exceptions were severe nausea and vomiting. Overall, almost half of the women compared with a third of the men experienced severe toxicity (P < .0001). Logistic regression confirmed the univariate findings while adjusting for the effects of study, dose, body mass index, and age. The differences were consistent across treatment cycles. Response rates and survival distributions were the same for both sexes. Conclusion: This study confirms an earlier finding that women receiving 5-FU-based chemotherapy in a 5-day bolus schedule experience toxicity more frequently and with more severity than men. These data raise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should be lower than that for men.

Original languageEnglish (US)
Pages (from-to)1491-1498
Number of pages8
JournalJournal of Clinical Oncology
Volume20
Issue number6
DOIs
StatePublished - Mar 15 2002

Fingerprint

Fluorouracil
Colorectal Neoplasms
Drug Therapy
Meta-Analysis
Stomatitis
Leukopenia
Nausea
Vomiting
Incidence
Logistic Models
Therapeutics
Neoplasms
National Cancer Institute (U.S.)
Alopecia
Diarrhea
Appointments and Schedules
Body Mass Index
Survival Rate
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. / Sloan, Jeff A; Goldberg, Richard M.; Sargent, Daniel J.; Vargas-Chanes, Delfino; Nair, Suresh; Cha, Steven S.; Novotny, Paul J.; Poon, Michael A.; O'Connell, Michael J.; Loprinzi, Charles Lawrence.

In: Journal of Clinical Oncology, Vol. 20, No. 6, 15.03.2002, p. 1491-1498.

Research output: Contribution to journalArticle

Sloan, JA, Goldberg, RM, Sargent, DJ, Vargas-Chanes, D, Nair, S, Cha, SS, Novotny, PJ, Poon, MA, O'Connell, MJ & Loprinzi, CL 2002, 'Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer', Journal of Clinical Oncology, vol. 20, no. 6, pp. 1491-1498. https://doi.org/10.1200/JCO.20.6.1491
Sloan, Jeff A ; Goldberg, Richard M. ; Sargent, Daniel J. ; Vargas-Chanes, Delfino ; Nair, Suresh ; Cha, Steven S. ; Novotny, Paul J. ; Poon, Michael A. ; O'Connell, Michael J. ; Loprinzi, Charles Lawrence. / Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 6. pp. 1491-1498.
@article{b034583c7c4f420a86cae544728078d4,
title = "Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer",
abstract = "Purpose: The toxicity profile of fluorouracil (5-FU)-based chemotherapy given on 5 consecutive days at doses of 370 to 450 mg/m2 has been well documented. A meta-analysis of six North Central Cancer Treatment Group (NCCTG) cancer control trials involving 786 patients indicated that women treated with this type of regimen experienced more severe stomatitis and leukopenia than men. After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken. Methods: Data for 1,093 women and 1,355 men from 12 different treatment arms were included. The primary end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, recorded with standard National Cancer Institute common toxicity criteria. Fisher's exact test was used to compare incidence and severity across sexes, supplemented by Forrest meta-analysis plots and logistic regression. Results: The incidence of four out of six toxicities studied was significantly greater for women than men; the exceptions were severe nausea and vomiting. Overall, almost half of the women compared with a third of the men experienced severe toxicity (P < .0001). Logistic regression confirmed the univariate findings while adjusting for the effects of study, dose, body mass index, and age. The differences were consistent across treatment cycles. Response rates and survival distributions were the same for both sexes. Conclusion: This study confirms an earlier finding that women receiving 5-FU-based chemotherapy in a 5-day bolus schedule experience toxicity more frequently and with more severity than men. These data raise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should be lower than that for men.",
author = "Sloan, {Jeff A} and Goldberg, {Richard M.} and Sargent, {Daniel J.} and Delfino Vargas-Chanes and Suresh Nair and Cha, {Steven S.} and Novotny, {Paul J.} and Poon, {Michael A.} and O'Connell, {Michael J.} and Loprinzi, {Charles Lawrence}",
year = "2002",
month = "3",
day = "15",
doi = "10.1200/JCO.20.6.1491",
language = "English (US)",
volume = "20",
pages = "1491--1498",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer

AU - Sloan, Jeff A

AU - Goldberg, Richard M.

AU - Sargent, Daniel J.

AU - Vargas-Chanes, Delfino

AU - Nair, Suresh

AU - Cha, Steven S.

AU - Novotny, Paul J.

AU - Poon, Michael A.

AU - O'Connell, Michael J.

AU - Loprinzi, Charles Lawrence

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Purpose: The toxicity profile of fluorouracil (5-FU)-based chemotherapy given on 5 consecutive days at doses of 370 to 450 mg/m2 has been well documented. A meta-analysis of six North Central Cancer Treatment Group (NCCTG) cancer control trials involving 786 patients indicated that women treated with this type of regimen experienced more severe stomatitis and leukopenia than men. After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken. Methods: Data for 1,093 women and 1,355 men from 12 different treatment arms were included. The primary end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, recorded with standard National Cancer Institute common toxicity criteria. Fisher's exact test was used to compare incidence and severity across sexes, supplemented by Forrest meta-analysis plots and logistic regression. Results: The incidence of four out of six toxicities studied was significantly greater for women than men; the exceptions were severe nausea and vomiting. Overall, almost half of the women compared with a third of the men experienced severe toxicity (P < .0001). Logistic regression confirmed the univariate findings while adjusting for the effects of study, dose, body mass index, and age. The differences were consistent across treatment cycles. Response rates and survival distributions were the same for both sexes. Conclusion: This study confirms an earlier finding that women receiving 5-FU-based chemotherapy in a 5-day bolus schedule experience toxicity more frequently and with more severity than men. These data raise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should be lower than that for men.

AB - Purpose: The toxicity profile of fluorouracil (5-FU)-based chemotherapy given on 5 consecutive days at doses of 370 to 450 mg/m2 has been well documented. A meta-analysis of six North Central Cancer Treatment Group (NCCTG) cancer control trials involving 786 patients indicated that women treated with this type of regimen experienced more severe stomatitis and leukopenia than men. After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken. Methods: Data for 1,093 women and 1,355 men from 12 different treatment arms were included. The primary end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, recorded with standard National Cancer Institute common toxicity criteria. Fisher's exact test was used to compare incidence and severity across sexes, supplemented by Forrest meta-analysis plots and logistic regression. Results: The incidence of four out of six toxicities studied was significantly greater for women than men; the exceptions were severe nausea and vomiting. Overall, almost half of the women compared with a third of the men experienced severe toxicity (P < .0001). Logistic regression confirmed the univariate findings while adjusting for the effects of study, dose, body mass index, and age. The differences were consistent across treatment cycles. Response rates and survival distributions were the same for both sexes. Conclusion: This study confirms an earlier finding that women receiving 5-FU-based chemotherapy in a 5-day bolus schedule experience toxicity more frequently and with more severity than men. These data raise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should be lower than that for men.

UR - http://www.scopus.com/inward/record.url?scp=0037087563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037087563&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.6.1491

DO - 10.1200/JCO.20.6.1491

M3 - Article

VL - 20

SP - 1491

EP - 1498

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -